Quanterix Stock Price, News & Analysis

Quanterix (NASDAQ: QTRX) reported Q2 2025 financial results, highlighting its recent acquisition of Akoya Biosciences. The company posted revenue of $24.5 million, down 29% year-over-year, with a GAAP gross margin of 46.2%. The quarter resulted in a net loss of $30.0 million.

Key developments include achieving 75% of their $85 million synergy and cost reduction target, launching new p-Tau assays for Alzheimer's research, and obtaining medical device registration approval in China. The company maintains $263.8 million in cash and equivalents, with adjusted cash usage of $2.6 million.

For full-year 2025, Quanterix expects revenues of $130-135 million, or $165-170 million on a pro forma basis including Akoya. The company projects achieving cash flow breakeven in 2026.

Quanterix (NASDAQ: QTRX), a biomarker detection technology company, has scheduled its second quarter 2025 financial results conference call for Thursday, August 7, 2025, at 4:30 p.m. ET. The company will release its Q2 2025 financial results after market close on the same day.

Investors can access the conference call by dialing (800) 715-9871 or (646) 307-1963 with conference ID 5591565. A live webcast will be available on the company's website, with an archived replay accessible for one year.

Quanterix (NASDAQ: QTRX), a biomarker detection company, has announced a cooperation agreement with Kent Lake Capital. The key terms include: appointment of a new independent director by December 1, 2025, through a joint search process involving both parties, plans to declassify the Board at the 2025 Annual Meeting, and adoption of a majority voting standard for uncontested director elections.

Kent Lake has agreed to withdraw its director nominations and support the Board's candidates, along with accepting standstill and voting commitments until 30 days before Quanterix's 2027 Annual Meeting nomination deadline. The agreement aims to maintain focus on company strategy and maximize benefits from the Akoya transaction.

Quanterix (NASDAQ: QTRX) has launched two first-to-market phospho-tau assays: p-Tau 205 and p-Tau 212 for Alzheimer's disease research. These novel assays, developed on the company's Simoa® platform, enable precise detection of tau phosphorylation sites associated with early-stage Alzheimer's disease.

The announcement coincides with the company's presence at AAIC 2025, where its Simoa® technology is featured in over 55 presentations. Following the recent Akoya Biosciences acquisition, Quanterix now combines fluid-based biomarker detection with spatial proteomics capabilities, offering researchers comprehensive tools for neurodegenerative disease research.

Quanterix (NASDAQ: QTRX), a biomarker detection company, has granted inducement restricted stock units (RSUs) to 20 new employees who joined through the Akoya Biosciences acquisition. The equity awards, totaling 267,269 RSU shares, were approved on July 8, 2025, under Nasdaq Rule 5635(c)(4).

The RSUs will fully vest after one year from the grant date, contingent on continued employment with Quanterix or its subsidiaries. These grants were made as part of the employees' compensation packages and served as inducements for their employment acceptance.

Quanterix (NASDAQ: QTRX) has completed its acquisition of Akoya Biosciences, creating an integrated platform for biomarker detection across blood and tissue. The transaction involved issuing 7.8 million shares of Quanterix common stock and $20 million in cash to Akoya equity holders.

The merger expands Quanterix's addressable market from $1 billion to $5 billion, focusing on neurology, oncology, and immunology markets. The combined company maintains $163 million in cash post-transaction and targets profitability by 2026. As part of the deal, Scott Mendel and Dr. Myla Lai-Goldman join Quanterix's Board, replacing Martin D. Madaus and Sarah Hlavinka.

Quanterix Corporation (NASDAQ: QTRX) announced that its HD-X Simoa Immunoassay Analyzer received Class 1 Medical Device registration in South Korea through HS Biosystems. The company has established new global collaborations with major laboratories including ARUP Laboratories, Neurogen Biomarking, NSW Health Pathology, and Rede D'Or. The Simoa platform enables ultrasensitive biomarker detection in blood for early disease detection, particularly for Alzheimer's disease through P-tau217 testing. The technology uniquely serves multiple purposes from research discovery to clinical trials and diagnostic testing. Notable implementations include ARUP's blood test for P-tau217 using Quanterix's SP-X platform and Neurogen's at-home blood biomarker collection test, expanding accessibility to early Alzheimer's detection and treatment options.

Kent Lake PR LLC, holding 6.9% of Quanterix Corporation (NASDAQ: QTRX) stock, has publicly criticized the company for failing to schedule its 2025 Annual Meeting, despite over a year passing since the last meeting on June 3, 2024. Kent Lake alleges this delay is a deliberate tactic by the Board to avoid shareholder accountability and push through the controversial Akoya merger without proper shareholder input. The activist investor suggests the Board is attempting to dilute existing shareholders' voting power by delaying until after the Akoya merger closes. Kent Lake demands immediate scheduling of the annual meeting and proposes including a board declassification measure, citing poor stock performance since the 2017 IPO under the current board structure.

Quanterix Corporation (NASDAQ: QTRX), a biomarker detection technology company, announced that President and CEO Masoud Toloue will present at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, Florida. The presentation is scheduled for June 9th, 2025, at 1:20 p.m. ET. The company will also conduct one-on-one meetings with institutional investors during the event. A live webcast of the presentation will be available through the Investors section of Quanterix's website, with a replay option available for a limited time after the conference.